Key facts, as of
As of November 4, 2026, Vertex Pharmaceuticals (VRTX) trades at $534.86, up 26.8% over the past year. Its 52-week range runs from $406.67 to $568.67; the price is 5.9% below that high. It is 5.9% below its all-time high of $568.67, reached in November 2026. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +636.7%, against +316.3% for the S&P 500 (SPY). It sits 11.3% above its 200-day average of $480.70, and its 50-day average is above the 200-day too: an uptrend on both averages. Its 30-day volatility is 32.4% annualized, which we rate high risk. It has a trailing P/E of 35.9.
Cite: Portfolio Terminal, "Vertex Pharmaceuticals (VRTX) stock analysis", 2026-11-04. https://portfolio-terminal.com/analyse/vrtx
Where it trades today
trading 79% of the way up its 52-week range
How the price has moved
How far it is from its record
Vertex Pharmaceuticals (VRTX) is 5.9% below its all-time high of $568.67, reached in November 2026. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +636.7%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- VRTX closes above its 50-day average ($522.62), and the 50-day sits above the 200-day ($480.70): on both averages the chart reads as an uptrend.
- At $534.86, VRTX is 5.9% below its 1-year high of $568.67, set on November 2, 2026, and 32.7% above its 1-year low of $403.16 (November 4, 2025).
- Over the past month VRTX rose 6.2%, from $503.50 to $534.86.
- VRTX trades at 35.9x its last twelve months of earnings and 26.7x the next twelve months' estimate, so analysts expect earnings 34.2% higher.
- Its P/E is 12.2% below the 40.8x median of the 2 other biotechnology companies we track (REGN, INCY).
- VRTX's 30-day volatility, 32.4% a year, works out to a typical daily move of about 2.0%.
- Yahoo Finance puts its beta at 0.28: over five years of monthly returns, VRTX moved about 0.28% for each 1% move of the S&P 500.
- The last session traded 0.2x VRTX's average daily volume of the 30 sessions before it.
What would change the read
- A close under the 50-day average, $522.62 (−2.3% from the last close), would turn the read to a pullback; under the 200-day, $480.70 (−10.1%), the longer rise is in question.
- A close above $568.67 (+6.3%) would be a new 1-year high; below $403.16 (−24.6%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for VRTX, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under biotechnology among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for VRTX by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for VRTX. Last refresh: Nov 4, 2026, 3:42 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Biotechnology.
What Vertex Pharmaceuticals does
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients…
What analysts expect
VRTX carries a buy consensus from 28 analysts, with an average price target of $578.71 versus $534.86 today (+8.2%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
VRTX generated $12.95B in trailing revenue (11.8% year over year), with a 30.7% net margin, against $175.10M of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $12.00B | $10.35B | $4.55B | $3.95B | $15.46 | $3.19B |
| 2024 | $11.02B | $9.49B | -$233.40M | -$535.60M | -$2.08 | -$978.00M |
| 2023 | $9.87B | $8.61B | $3.78B | $3.62B | $14.05 | $3.28B |
| 2022 | $8.93B | $7.85B | $4.25B | $3.32B | $12.97 | $3.93B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
VRTX is in 20 of the 54 ETFs we track. It weighs most in XLV: 1.98% of the fund, holding #13 of 62.
Famous investors who hold it
VRTX is in the latest 13F of 1 of the 15 famous investors we follow. Renaissance Technologies (Founded by Jim Simons) holds the most of it: 0.22% of the portfolio, position #84 of 2,931, as of Q2 2026.
How its figures compare with those peers
Companies in the same industry
VRTX beside the other companies Yahoo Finance files under biotechnology among the assets we track (REGN, MRNA, INCY, largest first).
VRTXyou are here$534.86$135.57B
REGNRegeneron Pharmaceuticals$949.76$98.25B
MRNAModerna Inc.$248.36$99.15B
INCYIncyte Corporation$118.97$24.25BWhat the chart is saying
In an uptrend, pressing toward $554.04 resistance.
uptrend- Price is 2.3% above its 50-day average and 11.3% above its 200-day.
- The 50-day crossed above the 200-day on 2026-06-29 (a “golden cross”).
- RSI at 55 is neither stretched nor washed out.
- The nearest ceiling is $554.04 (+3.6%), the nearest floor $501.40 (-6.3%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is VRTX valued right now?
Vertex Pharmaceuticals trades at 35.9 times its last twelve months of earnings and 26.7 times the next twelve months' estimate (Yahoo Finance, November 4, 2026). On the chart: in an uptrend, pressing toward $554.04 resistance. Price is 2.3% above its 50-day average and 11.3% above its 200-day.
What is the risk level of VRTX?
Based on 30-day volatility of 32.4%, VRTX has HIGH risk. Its beta of 0.28 means it has swung less than the S&P 500 over the last five years.
Does VRTX pay dividends?
Yahoo Finance shows no dividend yield for Vertex Pharmaceuticals (November 4, 2026).
How far is VRTX from its all-time high?
Vertex Pharmaceuticals is 5.9% below its all-time high of $568.67, reached in November 2026. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +636.7%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold VRTX?
20 of the 54 popular ETFs we track hold Vertex Pharmaceuticals. The largest weights: XLV (1.98%), JEPI (1.02%), MGK (0.61%), JEPQ (0.60%) and CNDX (0.55%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is VRTX?
0.20%, as of September 30, 2026: VRTX is holding #86 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $2.01 in Vertex Pharmaceuticals.
Which famous investors own VRTX?
Renaissance Technologies (0.22% of Founded by Jim Simons's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for VRTX?
The average analyst price target for Vertex Pharmaceuticals (VRTX) is $578.71 based on 28 analyst estimates, about 8.2% above the current price of $534.86. The published range runs from $350.00 to $725.00.
How much revenue does VRTX generate?
Vertex Pharmaceuticals reported $12.95B in trailing twelve-month revenue. Revenue growth is running at 11.8% year over year. Net margin sits at 30.7%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare VRTX with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.